Qure.ai

Qure.ai is a global medical-imaging AI company, founded in 2016, that builds deep-learning tools to detect and triage findings on radiology exams — most prominently chest X-rays (its qXR product), head CT (qER), and lung nodules (qCT). Its software reads an image and flags likely abnormalities, prioritizing urgent cases on the worklist and, in resource-limited settings, extending diagnostic reach where radiologists are scarce. With operations spanning Mumbai, New York, and London, Qure.ai is one of the most globally deployed radiology-AI vendors, reporting use across more than 100 countries.

The company has built an unusually broad regulatory portfolio: by early 2026 it reported 26 FDA indications across nine products, including a February 2026 batch of six new chest X-ray clearances that it framed as a category-leading position. Qure.ai's dual identity is notable — it is both a high-tech Western-market radiology vendor and a global-health tool used in tuberculosis and lung-cancer screening programs across Africa, Asia, and Latin America. Its main considerations are the ones common to all detection AI: clearances are indication-specific, performance depends on image quality and population, and the tools augment rather than replace the radiologist's read.